Erfolgreiche Behandlung einer therapierefraktären Akanthamöben-Keratitis mit systemischem Miltefosin und topischem Voriconazol

• Literatur

• 1 Zhang Y, Xu X, Wei Z. et al. The global epidemiology and clinical diagnosis of Acanthamoeba keratitis. J Infect Public Health 2023; 16: 841-852
• 2 Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 2009; 148: 487-499
• 3 Maycock NJ, Jayaswal R. Update on Acanthamoeba keratitis: diagnosis, treatment, and outcomes. Cornea 2016; 35: 713-720
• 4 Tavassoli S, Buckle M, Tole D. et al. The use of miltefosine in the management of refractory Acanthamoeba keratitis. Cont Lens Anterior Eye 2018; 41: 400-402
• 5 Chao M, Thongseesuksai T, Boonmars T. et al. Investigation of the in vitro cysticidal activity of miltefosine against Acanthamoeba spp. J Parasit Dis 2020; 44: 491-495
• 6 Thulasi P, Saeed HN, Rapuano CJ. et al. Oral miltefosine as salvage therapy for refractory Acanthamoeba keratitis. Am J Ophthalmol 2021; 223: 75-82
• 7 Bagga B, Sharma S, Gour RPS. et al. A randomized masked pilot clinical trial to compare the efficacy of topical 1 % voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02 % polyhexamethylene biguanide and 0.02 % chlorhexidine in the treatment of Acanthamoeba keratitis. Eye (Lond) 2021; 35: 1326-1333
• 8 Kashiwabuchi RT, De Freitas D, Alvarenga LS. et al. Corneal graft survival after therapeutic keratoplasty for Acanthamoeba keratitis. Acta Ophthalmol 2008; 86: 666-669
• 9 Kitzmann AS, Goins KM, Sutphin JE. et al. Keratoplasty for treatment of Acanthamoeba keratitis. Ophthalmology 2009; 116: 864-869
• 10 Naranjo A, Martinez JD, Miller D. et al. Systemic miltefosine as an adjunct treatment of progressive Acanthamoeba keratitis. Ocul Immunol Inflamm 2021; 29: 1576-1584
• 11 de la Presa M, Ibach M, Berdahl J. et al. Anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant Acanthamoeba keratitis. Cornea 2022; 41: 775-778
• 12 Hirabayashi KE, Lin CC, Ta CN. Oral miltefosine for refractory Acanthamoeba keratitis. Am J Ophthalmol Case Rep 2019; 16: 100555
• 13 Avdagic E, Chew HF, Veldman P. et al. Resolution of Acanthamoeba keratitis with adjunctive use of oral miltefosine. Ocul Immunol Inflamm 2021; 29: 278-281
• 14 Chen L, Kuang L, Ross AE. et al. Topical sustained delivery of miltefosine via drug-eluting contact lenses to treat Acanthamoeba keratitis. Pharmaceutics 2022; 14: 2750
• 15 McClellan K, Howard K, Niederkorn JY. et al. Effect of steroids on Acanthamoeba cysts and trophozoites. Invest Ophthalmol Vis Sci 2001; 42: 2885-2893
• 16 Robaei D, Carnt N, Minassian DC. et al. The impact of topical corticosteroid use before diagnosis on the outcome of acanthamoeba keratitis. Ophthalmology 2014; 121: 1383-1388
• 17 Carnt N, Robaei D, Watson SL. et al. The impact of topical corticosteroids used in conjunction with antiamoebic therapy on the outcome of Acanthamoeba keratitis. Ophthalmology 2016; 123: 984-990
• 18 Kaufman AR, Tu EY. Advances in the management of Acanthamoeba keratitis: a review of the literature and synthesized algorithmic approach. Ocul Surf 2022; 25: 26-36